Product Approval Time KPI

Product Approval Time is a critical KPI that measures the efficiency of product development and market readiness.

It directly influences time-to-market, operational efficiency, and customer satisfaction.

A shorter approval time can enhance a company's ability to respond to market demands, leading to improved financial health and competitive positioning.

Conversely, prolonged approval processes can hinder innovation and result in lost revenue opportunities.

Organizations that effectively manage this metric can achieve better forecasting accuracy and drive strategic alignment across departments.

Ultimately, optimizing product approval time contributes to stronger business outcomes and enhanced ROI.

How Product Approval Time Connects to Your Strategy

Product Approval Time belongs to one KPI group, Regulatory Affairs, a group of 58 KPIs monitoring the efficiency of a legal team's compliance processes. Ordered by priority, the group's headline co-metrics are Regulatory Compliance Rate, Safety Incident Reporting Compliance, Data Privacy Compliance Rate, Anti-Corruption Compliance Rate, Environmental Compliance Rate, Pharmacovigilance Compliance Rate, Anti-Money Laundering (AML) Compliance Rate, and Chemical Substance Compliance Rate. Product Approval Time ranks 41st of 58, placing it in the group's lower half: the group's top tier is dominated by compliance rate metrics across specific regulatory domains, while this KPI addresses timeliness of a specific process, submission through to clearance, rather than an ongoing compliance rate.

Its balanced scorecard perspective is internal, and it behaves as a process metric sitting alongside, rather than ahead of, the compliance rate measures that rank above it: a fast approval process is worth little if the underlying submission fails to meet Regulatory Compliance Rate or Pharmacovigilance Compliance Rate standards, so this KPI is best read as a secondary efficiency measure once compliance quality is established, not a substitute for it.

The concrete tension worth naming is with Pharmacovigilance Compliance Rate, since the group's description explicitly ties these KPIs to benchmarking against industry standards, and pharmacovigilance obligations are exactly the kind of thorough safety documentation that submission timelines put pressure on. Pushing Product Approval Time down by rushing a submission risks weakening the safety monitoring rigor that Pharmacovigilance Compliance Rate is meant to protect, and the two should be tracked side by side rather than optimized independently.

Measuring Product Approval Time in Practice

The submission date and clearance date behind this KPI typically live in a regulatory affairs tracking system or submission management platform, logged per product and per regulatory pathway. Joining that data honestly means tying each submission record to the specific agency and pathway it went through, since this group spans everything from drug applications to environmental and chemical substance clearances, and averaging across all of them together erases the differences that actually explain cycle length.

Before measuring, resolve where the clock starts: at internal readiness to submit, or at the agency's formal acceptance of the filing, since the two can be separated by internal handling time that has nothing to do with regulatory review itself. The endpoint needs the same scrutiny: an approval letter is not always the same milestone as clearance to ship or market, and mixing the two produces an inconsistent metric. Time the agency spends on a hold or an information request should also be handled with an explicit rule, since stopping or continuing the clock during that period changes what the metric actually measures, speed of review versus speed of the whole end to end process.

The segmentation that matters most here is by regulatory pathway and agency, not just by product line, since a routine renewal and a novel submission requiring extensive review are not comparable events. Priority review or expedited designations, where they exist, should also be split out rather than blended into a single average.

A common pitfall is letting a small number of approvals in a given period drive a volatile average, since regulatory affairs teams typically don't submit at high volume; another is conflating internal delay before submission with actual agency review time, which understates how efficient the regulatory function itself is being.

Common Pitfalls

Many organizations overlook the impact of lengthy product approval times on overall business performance.

• Failing to involve cross-functional teams early can create bottlenecks. When departments operate in silos, critical feedback may be delayed, extending the approval process unnecessarily.
• Neglecting to standardize approval workflows leads to confusion. Without clear guidelines, teams may struggle to navigate the process, resulting in inconsistent timelines and frustration.
• Overcomplicating approval criteria can stifle innovation. Excessive requirements may deter teams from proposing new ideas, ultimately slowing down product development.
• Ignoring data-driven insights can perpetuate inefficiencies. Organizations that do not analyze past approval times miss opportunities to identify trends and areas for improvement.

Improvement Levers

Streamlining product approval processes requires a focus on collaboration, clarity, and data utilization.

• Implement collaborative tools to enhance communication among teams. Platforms that facilitate real-time feedback can reduce delays and improve decision-making speed.
• Establish clear criteria for product approval to minimize confusion. By defining specific requirements, teams can better understand expectations and expedite the process.
• Utilize analytics to track approval times and identify bottlenecks. Regularly reviewing this data allows organizations to make informed adjustments and improve operational efficiency.
• Encourage a culture of innovation by simplifying the proposal process. Reducing barriers for new ideas can lead to faster product development and a more dynamic response to market needs.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Product Approval Time Benchmarks

We have 1 relevant benchmark in our benchmarks database.

Browse the Top Benchmarked KPIs in Regulatory Affairs

Reading the Benchmarks for Product Approval Time

Product Approval Time carries a single tracked source, the U.S. Food and Drug Administration's Prescription Drug User Fee Amendments program, specifically its PDUFA VI cycle, scoped to new drug applications in the United States pharmaceutical sector. That is a narrow, clearly defined regulatory timeline standard rather than a general benchmark for product approval across the many regulatory domains this group actually covers, from environmental permitting to chemical substance clearance to anti-money laundering related product controls.

A customer relying on this source should confirm their own product falls under an FDA new drug application pathway before treating PDUFA timelines as relevant at all; for any other regulatory domain represented in this group, this source offers no applicable reference point, and no comparable source is currently tracked for those domains. With only one source available, this module should be treated as a starting point for pharmaceutical submissions specifically, not as coverage of the KPI as a whole.

OKRs That Use Product Approval Time

Product Approval Time is not named directly in any of Regulatory Affairs' OKRs, but the group's best practice guidance explicitly calls for using timeliness KPIs, citing Regulatory Filings Timeliness by name, to avoid costly delays, and Product Approval Time is the same category of metric. The objective to accelerate response and resolution of regulatory issues, built on Regulatory Issue Resolution Time and Regulatory Change Management Effectiveness, gives this KPI a natural home: both are about how quickly the function moves once a regulatory process is underway.

A team could set an illustrative, directional key result under that objective focused on shortening approval time for its highest priority or highest volume submission pathway over an upcoming period, paired deliberately with a compliance rate metric such as Pharmacovigilance Compliance Rate or Regulatory Compliance Rate so that speed is never pursued at the expense of the submission quality those metrics are meant to protect.

See OKR Examples for Regulatory Affairs

Free Whitepaper

Want to achieve performance excellence in Regulatory Affairs? Download our in-depth whitepaper: Definitive Guide to Regulatory Affairs KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: